劉靜:女,中國科學院合肥物質科學研究院研究員 。 、
研究領域
通過化學生物學、藥物化學、分子影像學等方法發展新型化學小分子探針進行與重大疾病特別是癌症等相關的分子機制研究和新型診斷試劑的開發
學術論文
1.Hong Wu, Chen Hu, Aoli Wang, Ellen L. Weisberg, Yongfei Chen, et al, Jing Liu*, Nathanael S. Gray*, Liu Qingsong*, “Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia”, Leukemia, 2015, Jul 13. doi:10.1038/leu.2015.180. [IF: 10.431]
2.Hong Wu, Chen Hu, Aoli Wang, E L Weisberg, et al, Jing Liu* and Liu Qingsong*, “Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML”, Leukemia, 2015, Jul 3. doi: 10.1038/leu.2015.175. [IF: 10.431]
3.Daniel Nedelcu#, Jing Liu#, Yangqing Xu, Cindy Jao and Adrian Salic, “Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signaling”, Nat. Chem. Biol., 2013, 9, 557-564. (#co-first author) [IF: 12.996]
4.Jing Liu, Yangqing Xu, Dan Stoleru, and Adrian Salic, “Imaging protein synthesis in cells and tissues with an alkyne analog of puromycin”, PNAS, 2012, 109, 413-418. (highlighted in Nature Methods) [IF: 9.674]
5.Jing Liu, Yi Hu, David L. Waller, Junfeng Wang and Qingsong Liu, “Natural products as kinase inhibitors”, Nat. Prod. Rep., 2012, 29, 392-403. [IF: 10.107]
6.Jing Liu, Fouad Brahimi, H. Uri Saragovi, and Kevin Burgess, “Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists”, J. Med. Chem., 2010, 53, 5044-5048. [IF: 5.447]